Clinical Trials
Pumitamig + Chemotherapy vs. Nivolumab + Chemotherapy in untreated metastatic Gastric, Gastroesophageal, or GEJ
Disease Type: Gastrointestinal
A Blinded, Randomized, Phase 2/3 Study of Pumitamig in Combination with Chemotherapy Versus Nivolumab in Combination with Chemotherapy in Participants with Previously Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma
Locations
Alleghany , Blacksburg , Roanoke , Salem , Wytheville